Molecular alterations of KIT and PDGFRA in GISTs: Evaluation of a Portuguese series

Journal of Clinical Pathology

Volumn 61, Issue 2, 2008, Pages 203-208

  Gomes, A L ^a   Gouveia, A ^b,c   Capelinha, A F ^b,c   De La Cruz, D ^b   Silva, P ^b,c   Reis, R M ^a   Pimenta, A ^b,c   Lopes, José Manuel ^b,c,d  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d NONE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

STEM CELL FACTOR RECEPTOR; DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CHROMOSOME DELETION 4; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; AMINO ACID SEQUENCE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 38849209234     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.047043     Document Type: Article

References (33)

1. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology 2006;48:83-96.
2. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors - a review. Acta Orthop Scand Suppl 2004;75:62-71.
3. Miettinen M, Virolainen M, Maarit-Sarlomo-Rikala. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995;19:207-16.
4. Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Clin Oncol 2001;6:1-5.
5. Miettinen M, Blay JY, Sobin LH. Mesenchymal tumours of the stomach. In: Hamilton SR and Aaltonen LA, eds. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:62-5.
6. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 2004;61:2924-31.
7. Roskoski R. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 2005;338:1307-15.
8. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004;61:2535-48.
9. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
11. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-9.
12. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006;59:557-63.
13. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
14. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64.
15. Baker DE. Imatinib mesylate. Rev Gastroenterol Disord 2002;2:75-86.
16. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
17. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002;10:81-9.
18. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
19. Gomes AL, Bardales RH, Milanezi F, et al. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 2007;127:1-8.
20. Reis RM, Martins A, Ribeiro SA, et al. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cell Oncol 2005;27:319-26.
21. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
22. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
23. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7.
24. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006;368:1303-4.
25. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
26. Feng F, Liu XH, Xie Q, et al. Expression and mutation of c-kit gene in gastrointestinal stromal tumors. World J Gastroenterol 2003;9:2548-51.
27. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-94.
28. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190-8.
29. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887-95.
30. Penzel R, Aulmann S, Moock M, et al. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005;58:634-9.
31. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24.
32. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12:1743-9.
33. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7.